Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis.

about

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis.

Item

http://www.wikidata.org/entity/Q49785414

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Chemotherapy plus Panitumumab ...... ectal Cancer: A Meta-analysis.

@en

Chemotherapy plus Panitumumab ...... ectal Cancer: A Meta-analysis.

@nl

type

Item

label

Chemotherapy plus Panitumumab ...... ectal Cancer: A Meta-analysis.

@en

Chemotherapy plus Panitumumab ...... ectal Cancer: A Meta-analysis.

@nl

prefLabel

Chemotherapy plus Panitumumab ...... ectal Cancer: A Meta-analysis.

@en

Chemotherapy plus Panitumumab ...... ectal Cancer: A Meta-analysis.

@nl

P1476

Chemotherapy plus Panitumumab ...... ectal Cancer: A Meta-analysis.

@en

P2093

Rui Zhao

http://www.w3.org/2001/XMLSchema#string

Xiaoting Wu

http://www.w3.org/2001/XMLSchema#string

Yaping Cui

http://www.w3.org/2001/XMLSchema#string

Yong Zhou

http://www.w3.org/2001/XMLSchema#string

Yuqian Huang

http://www.w3.org/2001/XMLSchema#string

Zhigui Li

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis

A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

P2888

s41598-017-19001-6

P304

510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1038/S41598-017-19001-6

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100212546

http://www.w3.org/2001/XMLSchema#string

P698

29323221

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

bevacizumab

chemotherapy

P932

5764984

http://www.w3.org/2001/XMLSchema#string